S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Why Your IRA Could Crash on January 16th? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
Why Your IRA Could Crash on January 16th? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Why Your IRA Could Crash on January 16th? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
Why Your IRA Could Crash on January 16th? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Why Your IRA Could Crash on January 16th? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
Why Your IRA Could Crash on January 16th? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Why Your IRA Could Crash on January 16th? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
Why Your IRA Could Crash on January 16th? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
NASDAQ:CTMX

CytomX Therapeutics - CTMX Stock Forecast, Price & News

$1.71
0.00 (0.00%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.66
$1.71
50-Day Range
$1.19
$1.91
52-Week Range
$1.17
$6.97
Volume
570,969 shs
Average Volume
3.19 million shs
Market Capitalization
$113.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.84

CytomX Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.09 Rating Score
Upside/​Downside
183.3% Upside
$4.84 Price Target
Short Interest
Healthy
1.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.61
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.23) to ($0.84) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

508th out of 1,034 stocks

Pharmaceutical Preparations Industry

231st out of 502 stocks

CTMX stock logo

About CytomX Therapeutics (NASDAQ:CTMX) Stock

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Receive CTMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CTMX Stock News Headlines

CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron
CytomX Therapeutics Provides Strategic Update
Analyst Ratings for CytomX Therapeutics
See More Headlines
Receive CTMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CTMX Company Calendar

Last Earnings
11/04/2021
Today
12/04/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTMX
Employees
174
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.84
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+183.3%
Consensus Rating
Hold
Rating Score (0-4)
2.09
Research Coverage
11 Analysts

Profitability

Net Income
$-83,610,000.00
Net Margins
-135.65%
Pretax Margin
-135.65%

Debt

Sales & Book Value

Annual Sales
$69.57 million
Book Value
$0.43 per share

Miscellaneous

Free Float
61,789,000
Market Cap
$113.00 million
Optionable
Optionable
Beta
0.47

Key Executives

  • Sean A. McCarthySean A. McCarthy
    Chairman, President & Chief Executive Officer
  • Chris Ogden
    Chief Financial & Accounting Officer
  • Marcia P. Belvin
    Senior Vice President & Head-Research
  • Lloyd A. Rowland
    Secretary, Chief Compliance Officer & Senior VP
  • Danielle Olander
    Senior VP-Talent & Systems Development













CTMX Stock - Frequently Asked Questions

Should I buy or sell CytomX Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 1 sell rating, 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CTMX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTMX, but not buy additional shares or sell existing shares.
View CTMX analyst ratings
or view top-rated stocks.

What is CytomX Therapeutics' stock price forecast for 2023?

11 Wall Street analysts have issued 1-year price targets for CytomX Therapeutics' shares. Their CTMX share price forecasts range from $1.50 to $11.00. On average, they expect the company's share price to reach $4.84 in the next twelve months. This suggests a possible upside of 183.3% from the stock's current price.
View analysts price targets for CTMX
or view top-rated stocks among Wall Street analysts.

How have CTMX shares performed in 2022?

CytomX Therapeutics' stock was trading at $4.33 at the start of the year. Since then, CTMX stock has decreased by 60.5% and is now trading at $1.71.
View the best growth stocks for 2022 here
.

When is CytomX Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our CTMX earnings forecast
.

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) released its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.05. The biotechnology company had revenue of $17.59 million for the quarter, compared to analysts' expectations of $18.53 million. CytomX Therapeutics had a negative trailing twelve-month return on equity of 166.29% and a negative net margin of 135.65%. During the same quarter in the previous year, the firm posted ($0.32) earnings per share.

What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO?

12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend.

What other stocks do shareholders of CytomX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BVF Inc. IL (9.98%), Vanguard Group Inc. (6.87%), Tang Capital Management LLC (5.30%), Renaissance Technologies LLC (2.73%), BlackRock Inc. (2.72%) and Jacobs Levy Equity Management Inc. (1.66%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Jeffrey B Landau, Lloyd A Rowland and Sean A Mccarthy.
View institutional ownership trends
.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $1.71.

How much money does CytomX Therapeutics make?

CytomX Therapeutics (NASDAQ:CTMX) has a market capitalization of $113.00 million and generates $69.57 million in revenue each year. The biotechnology company earns $-83,610,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

How many employees does CytomX Therapeutics have?

The company employs 174 workers across the globe.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytomx.com. The biotechnology company can be reached via phone at (605) 515-3185, via email at ckeenan@cytomx.com, or via fax at 650-351-0353.

This page (NASDAQ:CTMX) was last updated on 12/4/2022 by MarketBeat.com Staff